Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Novo Nordisk A/S (NVO) vs J M Smucker Co (SJM) Price & Performance

Novo Nordisk A/STrade
J M Smucker CoTrade

Price performance (Past 24H)

Key statistics

Novo Nordisk A/S vs J M Smucker Co — how do they compare? Novo Nordisk A/S trades at $38.63 (market cap $165.31B), while J M Smucker Co trades at $119.57 (market cap $12.76B). The key difference: Novo Nordisk A/S is far larger — about 13× J M Smucker Co's market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Novo Nordisk A/S for 116 Days and J M Smucker Co for 74 Days on average.

NVOSJM
Market Cap
$165.31B$12.76B
Volume
11,432,8381,300,545
Sector
HealthConsumer Staples
52-Week High
$63.98$132.34
52-Week Low
$35.29$89.53
Typical Hold Time
116 Days74 Days
Enterprise Value
$179.56B$19.61B
Dividend Yield
4.71%3.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Novo Nordisk A/S

Novo Nordisk (NVO) trades at $38.41, up 0.38% with strong fundamentals including 35.35% net margin and consistent earnings beats. The stock shows bearish technical signals but maintains robust profitability with $102.43B net income. Recent news highlights pipeline developments including Wegovy pill data and FDA reviews, while competition with Eli Lilly intensifies in the obesity drug market.

NVO presents a compelling value opportunity with a 9.66 P/E ratio and 59% upside to the $44.67 consensus target. However, technical weakness and competitive pressures from Lilly's new drug candidates pose near-term risks. The company's strong cash flow generation and 59.82% ROE support long-term growth prospects despite regulatory uncertainties.

J M Smucker Co

SJM stock trades at $119.27, up 2.88% today, with a bullish technical signal from moving averages. The company shows strong earnings momentum with three consecutive quarterly beats, though 2025 results were impacted by a net loss of $1.23B. Analyst consensus is positive with a $138.23 price target, representing 16% upside potential. Recent news highlights strong execution and raised 2027 guidance, while technical indicators show support at $118 and resistance at $120.

The outlook remains cautiously optimistic with earnings momentum and raised guidance supporting upside, but investors face risks from volatile profitability, high debt levels, and competitive pressures in consumer staples. The stock offers value with reasonable P/S and EV/EBITDA multiples, though the elevated P/E ratio requires sustained earnings improvement to justify current valuation levels.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

NVO
96% Buy4% Sell
Avg holding period · 116 Days
SJM

No sentiment data available yet.

Top news

Latest headlines on both assets

About Novo Nordisk A/S

With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.

Read more on NVO →

About J M Smucker Co

J.M. Smucker is a packaged food company that primarily operates in the U.S. retail channel (87% of fiscal 2022 revenue), but also in U.S. food-service (7%), and international (6%). Its largest segment is pet food and treats (36% of 2022 revenue), with popular brands such as Milk-Bone, Meow Mix, 9Lives, Kibbles 'n Bits, Nature's Recipe, and Rachael Ray Nutrish. Its second-largest category is coffee (35% across channels) with the number-two brand Folgers and number-six Dunkin'. Other large categories are peanut butter (10%), with number-one Jif, fruit spreads (5%) with number-one Smucker's, and frozen hand-held foods (6%) with number-one Uncrustables.

Read more on SJM →